(Reuters) -Regeneron Pharmaceuticals Inc beat Wall Street estimates for first-quarter profit on Thursday, driven by strong demand for eczema treatment Dupixent.
Quarterly sales of Dupixent, recorded by Regeneron’s partner Sanofi, rose about 37% to $2.49 billion. Analysts had expected $2.38 billion, according to an average of 6 analysts’ estimates polled by Refinitiv.
Advertisement
Regeneron’s total revenue of $3.16 billion beat expectations of $3 billion in the quarter.
Excluding items, the company reported a profit of $10.09 per share, above estimates of $9.56.
(Reporting by Sriparna Roy and Raghav Mahobe in Bengaluru; Editing by Devika Syamnath)
By: OAN
Advertisement
(function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13348268193035366,size:[0, 0],id:”ld-4546-3812″});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src=”//cdn2.lockerdomecdn.com/_js/ajs.js”;j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,”script”,”ld-ajs”);